Роль тамоксифена в терапии метастатического рака яичника

Читать PDF

Аннотация

Рак яичника – одна из наиболее часто встречающихся злокачественных опухолей у женщин. Несмотря на высокую чувствительность к противоопухолевой химиотерапии (ремиссия отмечается более чем у 80% пациенток, получающих в качестве
1-й линии стандартную терапию препаратами платины и паклитаксела), наступают рецидив заболевания и резистентность к дальнейшим видам терапии. Таким образом, возникает необходимость разработки новых нетоксичных методов терапии с учетом биологических свойств опухоли. Тамоксифен улучшает результаты у интенсивно предлеченных больных c метастатическим раком яичника и обладает при этом невысокой токсичностью.

Ключевые слова: метастатический рак яичника, антиэстрогенная терапия, тамоксифен.

________________________________________________

Ovarian cancer is one of the most widely spread among women malignant tumors. Despite high sensitivity to anti-cancer chemotherapy (responses are awaited from more than 80% of women, receiving standard therapy with platinum and paclitaxel) recurrence of the disease takes place and the tumor becomes resistant to further therapy. Thus, it becomes necessary to invent new types of non-toxic therapy, taking into consideration biological qualities of the tumor. Tamoxifen therapy has efficacy in previously intensively treated patients with metastatic ovarian cancer, and it has low toxicity as well.

Key words: metastatic ovarian cancer, anti-oestrogen therapy, tamoxifen.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225–49.
2. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69 (2): 103–8.
3. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354 (1): 34–43.
4. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5 (1): 26–35.
5. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. 2005; 365 (9453): 60–2.
6. Jakesz R, Jonat W, Gnant M et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366 (9484): 455–62.
7. Schwartz PE, Keating G, MacLusky N et al. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982; 59 (5): 583–8.
8. Shirey DR, Kavanagh JJ Jr, Gershenson DM et al. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985; 66 (4): 575–8.
9. Slevin ML, Harvey VJ, Osborne RJ et al. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1986; 22 (3): 309–12.
10. Osborne RJ, Malik ST, Slevin ML et al. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer 1988; 57 (1): 115–6.
11. Ahlgren JD, Ellison NM, Gottlieb RJ et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11 (10): 1957–68.
12. Van der Vange N, Greggi S, Burger CW et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995; 34 (6): 813–20.
13. Van Der Velden J, Gitsch G, Wain GV et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5 (4): 301–5.
14. Marth C, Sorheim N, Kaern J, Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma. Int J Gynecol Cancer 1997; 7: 256–61.
15. Markman M, Webster K, Zanotti K et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004; 93 (2): 390–3.
16. Karagol H, Saip P, Uygun K et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007; 24 (1): 39–43.
17. Markman M, Webster K, Zanotti K et al. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2004; 94 (2): 404–8.
18. Schwartz PE, Chambers JT, Kohorn EI et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989; 63 (6): 1074–8.
19. Millward MJ, Cantwell BM, Lien EA et al. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992; 28A (4–5): 805–10.
20. Benedetti PP, Greggi S, Amoroso M et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer 2001; 11 (6): 438–44.

Авторы

И.С.Давиденко, М.В.Казанцева, Н.В.Порханова, М.Р.Оганян

ГБУЗ Клинический онкологический диспансер №1 Минздрава Краснодарского края

________________________________________________

I.S.Davidenko, M.V.Kazantseva, N.V.Porhanova, M.R.Ohanyan

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.